The role of hippocampal KCNQ2 channel in antidepressant actions of ketamine.
Neuron July 1, 2022 DOI: 10.1016/j.neuron.2022.05.027 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Esketamine Ketamine |
| Key points | The commentary reports that KCNQ2 in ventral hippocampal glutamatergic neurons is essential for ketamine's sustained antidepressant-like effects, and argues that KCNQ2 activators could be developed as antidepressants without ketamine's side effects. |
Abstract
In this issue of Neuron, Lopez et al. report that KCNQ2 (potassium voltage-gated channel subfamily Q member 2) is essential for the sustained antidepressant-like effects of ketamine in glutamatergic neurons of the ventral hippocampus. This study implies that KCNQ2 activators can be novel antidepressants without the ketamine side effects.
Citations in the library
Cited by 15
- Arketamine, a new rapid-acting antidepressant: A historical review and future directions Neuropharmacology August 14, 2022
- Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics? European Archives of Psychiatry and Clinical Neuroscience February 27, 2024
- Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms. Biomedicines October 9, 2024
- Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice Pharmacology, Biochemistry, and Behavior December 5, 2022
- Arketamine for cognitive impairment in psychiatric disorders European Archives of Psychiatry and Clinical Neuroscience February 14, 2023
and 10 more in the library
Cites 5
- Ketamine: a paradigm shift for depression research and treatment Neuron March 1, 2019
- Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor Molecular Psychiatry May 7, 2021
- Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochemical Pharmacology July 1, 2020
- Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine Molecular Psychiatry November 24, 2021
- Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2. Neuron May 1, 2022